Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Cost of Revenue (2016 - 2025)

Mimedx's Cost of Revenue history spans 15 years, with the latest figure at $19.1 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 12.69% year-over-year to $19.1 million; the TTM value through Dec 2025 reached $73.0 million, up 21.54%, while the annual FY2025 figure was $73.0 million, 21.54% up from the prior year.
  • Cost of Revenue for Q4 2025 was $19.1 million at Mimedx, up from $18.7 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $19.1 million in Q4 2025 and bottomed at $7.1 million in Q4 2021.
  • The 5-year median for Cost of Revenue is $13.7 million (2023), against an average of $13.8 million.
  • The largest annual shift saw Cost of Revenue plummeted 34.38% in 2021 before it soared 102.44% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $7.1 million in 2021, then skyrocketed by 102.44% to $14.4 million in 2022, then fell by 3.67% to $13.8 million in 2023, then grew by 22.16% to $16.9 million in 2024, then grew by 12.69% to $19.1 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's Cost of Revenue are $19.1 million (Q4 2025), $18.7 million (Q3 2025), and $18.7 million (Q2 2025).